Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 30413378

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2018 Dec
First author
Solomon BJ

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Dec;19(12):1555-1557. doi: 10.1016/S1470-2045(18)30789-7.
    note
    Source null
    related pmid
    30413381
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2019 Jan;20(1):e10. doi: 10.1016/S1470-2045(18)30927-6.
    note
    Source null
    related pmid
    30614467
    relationship
    Erratum in
  3. citation
    Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S383-S386. doi: 10.21037/tlcr.2019.05.10.
    note
    Source null
    related pmid
    32038920
    relationship
    Comment in

Authors and identifiers

  1. name
    Solomon BJ
    type
    Author
  2. name
    Besse B
    type
    Author
  3. name
    Bauer TM
    type
    Author
  4. name
    Felip E
    type
    Author
  5. name
    Soo RA
    type
    Author
  6. name
    Camidge DR
    type
    Author
  7. name
    Chiari R
    type
    Author
  8. name
    Bearz A
    type
    Author
  9. name
    Lin CC
    type
    Author
  10. name
    Gadgeel SM
    type
    Author
  11. name
    Riely GJ
    type
    Author
  12. name
    Tan EH
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Solomon BJ
    type
    Author
  2. name
    Besse B
    type
    Author
  3. name
    Bauer TM
    type
    Author
  4. name
    Felip E
    type
    Author
  5. name
    Soo RA
    type
    Author
  6. name
    Camidge DR
    type
    Author
  7. name
    Chiari R
    type
    Author
  8. name
    Bearz A
    type
    Author
  9. name
    Lin CC
    type
    Author
  10. name
    Gadgeel SM
    type
    Author
  11. name
    Riely GJ
    type
    Author
  12. name
    Tan EH
    type
    Author
bibliography ids
  1. nci-bib-cc2fc90acd6c73fb36327920
book metadata
content sha256
9074cd1c8f553f7bd2b55b6a49c8a49d1986b6af67f4c777dfe3728d8a237fe0
document type
citation
dois
  1. 10.1016/S1470-2045(18)30649-1
electronic publication date
display
2018 Nov 6
precision
day
year
2018
evidence scope
bibliographic_metadata_only
id
pubmed:30413378
immutable id
pubmed:30413378@9074cd1c8f553f7bd2b55b6a49c8a49d1986b6af67f4c777dfe3728d8a237fe0
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
12
name
The Lancet. Oncology
nlm unique id
100957246
pages
1654-1667
volume
19
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Dec;19(12):1555-1557. doi: 10.1016/S1470-2045(18)30789-7.
    note
    Source null
    related pmid
    30413381
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2019 Jan;20(1):e10. doi: 10.1016/S1470-2045(18)30927-6.
    note
    Source null
    related pmid
    30614467
    relationship
    Erratum in
  3. citation
    Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S383-S386. doi: 10.21037/tlcr.2019.05.10.
    note
    Source null
    related pmid
    32038920
    relationship
    Comment in
outcomes validated
false
pmid
30413378
provenance
batch id
438b2803888025c6cf56
provider
NCBI PubMed ESummary
record sha256
a72dc4aa1155543741586f0566fbca9ab39d7c2f2e208bde461d2bdac7bbf0cf
response sha256
0adf5ff07d3aa03a45feef5e4b7998e2ddea370eb9d1c6aa9134c5fd329767e6
retrieved at
2026-09-09T23:47:36.359220+00:00
publication date
display
2018 Dec
precision
month
year
2018
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/30413378/
title
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.

Preserved source evidence · Not medical advice